KDR and neoplasm: Our data demonstrate that VEGFR2 inhibition, either as monotherapy or in combination with chemotherapy, promotes anti-tumor responses in several pediatric cancer models and further supports clinical investigation of ramucirumab in combination with other therapies for pediatric cancer patients.